| Size | Price | |
|---|---|---|
| 500mg | ||
| 1g | ||
| Other Sizes |
| Targets |
2-Amino-1,3-bis(carboxylethoxy)propane HCl salt does not have pharmacological targets as it is a chemical linker and bioconjugation reagent rather than a therapeutic agent. Its function is to covalently attach target-binding moieties (ligands for E3 ubiquitin ligases and target proteins) in PROTAC molecules. No receptor binding, enzyme inhibition, or other pharmacological target activities are applicable to this compound.
|
|---|---|
| ln Vitro |
One ligand is for an E3 ubiquitin ligase, and the other is for the target protein; these two ligands are joined by a linker to form PROTACs. The intracellular ubiquitin-proteasome system is utilized by PROTACs to specifically destroy target proteins[1].
No in vitro activity data (e.g., IC50, EC50) for 2-amino-1,3-bis(carboxylethoxy)propane HCl salt are applicable or available as this compound is a chemical linker and bioconjugation reagent rather than a pharmacologically active compound. Its utility is assessed by conjugation efficiency, purity, and suitability for PROTAC synthesis rather than biological activity. |
| ln Vivo |
No in vivo activity data for 2-amino-1,3-bis(carboxylethoxy)propane HCl salt are applicable or available as this compound is a chemical linker and bioconjugation reagent rather than a pharmacologically active compound. The compound is not intended for therapeutic use and has no reported pharmacological effects in animal models. Its stability and reactivity in biological matrices may be assessed but no therapeutic efficacy data exist.
|
| Enzyme Assay |
No published experimental protocols for cell-free enzyme/receptor binding assays are applicable for 2-amino-1,3-bis(carboxylethoxy)propane HCl salt as it is a bioconjugation reagent. Standard PROTAC synthesis protocols involve conjugation of the linker to a target-binding ligand and an E3 ligase-binding ligand. The carboxylic acid groups are typically activated with EDC/NHS in MES buffer (pH 5.5-6.0) at room temperature for 15-30 minutes, followed by reaction with amine-containing molecules in PBS buffer (pH 7.4) at 4-25°C for 2-24 hours. The amino group can be used for further functionalization.
|
| Cell Assay |
No published in vitro cell-based experimental protocols are applicable for 2-amino-1,3-bis(carboxylethoxy)propane HCl salt as it is a bioconjugation reagent. For related PROTAC studies, standard protocols involve treatment of cultured cells with PROTAC molecules synthesized using this linker at concentrations of 0.001-10 μM for 4-24 hours. Target protein degradation is assessed by Western blot. Cell viability is assessed by MTT or CellTiter-Glo. Ubiquitination is confirmed by immunoprecipitation and ubiquitin Western blot.
|
| Animal Protocol |
No published in vivo animal experimental protocols are applicable for 2-amino-1,3-bis(carboxylethoxy)propane HCl salt as it is a bioconjugation reagent rather than a therapeutic agent. For related PROTAC studies, standard protocols involve administration of PROTAC molecules to tumor-bearing xenograft mouse models via intravenous or intraperitoneal injection at doses of 1-50 mg/kg, with assessment of target protein degradation in tumor tissues by Western blot, monitoring of tumor growth, and evaluation of pharmacokinetics by LC-MS/MS.
|
| References |
| Molecular Formula |
C9H17NO6
|
|---|---|
| Molecular Weight |
235.23438334465
|
| Exact Mass |
235.105
|
| CAS # |
1020112-73-5
|
| PubChem CID |
90160341
|
| Appearance |
Typically exists as solid at room temperature
|
| LogP |
-4.2
|
| tPSA |
119
|
| Hydrogen Bond Donor Count |
3
|
| Hydrogen Bond Acceptor Count |
7
|
| Rotatable Bond Count |
10
|
| Heavy Atom Count |
16
|
| Complexity |
198
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
C(COCC(COCCC(=O)O)N)C(=O)O
|
| InChi Key |
HWQYUSUCQZDSSK-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C9H17NO6/c10-7(5-15-3-1-8(11)12)6-16-4-2-9(13)14/h7H,1-6,10H2,(H,11,12)(H,13,14)
|
| Chemical Name |
3,3'-((2-aminopropane-1,3-diyl)bis(oxy))dipropionic acid
|
| Synonyms |
2-Amino-1,3-bis(carboxylethoxy)propane HCl salt HUN-12735 HUN12735HUN 12735
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80: Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 :Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400  (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 4.2512 mL | 21.2558 mL | 42.5116 mL | |
| 5 mM | 0.8502 mL | 4.2512 mL | 8.5023 mL | |
| 10 mM | 0.4251 mL | 2.1256 mL | 4.2512 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration: mg/mL;
Method for preparing DMSO stock solution: mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation::Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.